Seeking Alpha

Acadia (ACAD) shares more than triple in value after being freed from a trading halt following...

Acadia (ACAD) shares more than triple in value after being freed from a trading halt following news that its pimavanserin drug reduced psychotic episodes in patients with Parkinson's disease compared with a placebo in a Phase III trial. Acadia now needs to conduct another late-stage study to confirm the results - two similar trials failed to show a substantial fall in psychotic episodes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector